NCT02452450已完成1 期
Ibuprofen and Paracetamol Pharmacokinetic Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 43
- 主要终点
- Time to the maximum concentration (Cmax) of the reference Ibuprofen
研究概览
简要总结
The purpose of this study was to determine rates of absorption of Ibuprofen and Paracetamol formulations.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age: > 18 to < 50 years.
- •Sex: Male and female subjects are eligible for entry.
- •Female subject of child bearing potential with a negative pregnancy test at the screening visit and willing to use an effective method of contraception, if applicable
- •Female subject of non-child bearing potential with negative pregnancy test at the screening visit.
- •Male subject willing to use an effective method of contraception.
- •Status: Healthy volunteers with a body mass index of >18 and <30 kg/m
- •Absence of relevant abnormalities in the clinical examination, ECG, drug and safety analysis.
- •Subjects who have given written informed consent
排除标准
- •Pregnant or lactating female subjects.
- •A history of significant disease of any body-system.
- •Any condition that may currently interfere with the absorption, distribution, metabolism or excretion of drugs.
- •A history of allergy or intolerance (including angio-oedema, urticaria, bronchospasm and rhinitis) related to treatment with ibuprofen, aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs), paracetamol, or the excipients of the formulations.
- •A history of peptic or duodenal ulcers or gastro-intestinal bleed or upper gastro-intestinal bleed, or other significant gastro-intestinal disorders.
- •A history of frequent dyspepsia, e.g., heartburn or indigestion.
- •A history of migraine.
- •A history of psychotic illness, attempted suicide or parasuicide.
- •Current smokers and ex-smokers who have smoked within 6 months.
- •A history of drug abuse (including alcohol).
- •High consumption of stimulating drinks
- •Those with positive drugs of abuse screen including alcohol on any occasion throughout the study.
- •Ingestion of a prescribed drug at any time in the 14 days before dosing with study medication (excluding hormonal contraceptives and hormone replacement therapy), or consumption of enzyme inhibitors or inducers during the previous month (such as barbiturates, carbamazepine, erythromycin, phenytoin, etc).
- •Ingestion of an over-the-counter preparation within 7 days before dosing with study medication, including herbal medications, vitamin/fish oil supplements, ibuprofen and other NSAIDs and paracetamol.
- •Donation of blood in quantity in the previous 12 weeks before enrolment into the study
- •Known human immune deficiency virus (HIV) positive status, or a positive viral serology screen.
- •Topical use of ibuprofen within 7 days before dosing with study medication
- •Those previously randomised into this study.
- •Employee at study site.
- •Partner or first degree relative of the investigator.
- •Those with an ibuprofen level > 10 ng/ml as determined at pre-study screening visit 2 (Part 2 (Pivotal Phase) of the study only).
- •Those who are unwilling to consume gelatin of animal origin (Part 2 (Pivotal Phase) of the study only).
- •Those who have participated in a clinical trial in the previous 12 weeks
- •Those unable in the opinion of the Investigator to comply fully with the study requirements.
研究组 & 干预措施
Ibuprofen lysine
Experimental
干预措施: Ibuprofen Lysine (Drug)
Ibuprofen sodium
Experimental
干预措施: Ibuprofen Sodium (Drug)
Ibuprofen liquid capsules
Experimental
干预措施: Ibuprofen Liquid Capsules (Drug)
Ibuprofen acid
Active Comparator
干预措施: Ibuprofen Acid (Drug)
Paracetamol
Active Comparator
干预措施: Paracetamol (Drug)
结局指标
主要结局
Time to the maximum concentration (Cmax) of the reference Ibuprofen
时间窗: 0-4hr
Time to the first extrapolated non-zero concentration (Tlag)
时间窗: 0-4hr
Time to the maximum concentration (Tmax)
时间窗: 0-4hr
次要结局
- Time to the lower therapeutic level reaching at least 5 µg/ml (T5.0) for ibuprofen and paracetamol(0-4hr)
- Time to the mid therapeutic level reaching at least 8.4 µg/ml (T8.4) for ibuprofen and 10 µg/ml (T10.0) for paracetamol(0-4hr)
- Time to the higher therapeutic level reaching at least 10.0 µg/ml (T10.0) for ibuprofen and 20 µg/ml (T20.0) for paracetamol(0-4hr)
- Partial area under the curve (AUCs) at each nominal blood sampling time-point(0-4hr)
- The area under the curve up to the median Tmax for the ibuprofen reference product (AUCTmaxRef)(0-4hr)
- The plasma concentration at each planned nominal time-point (Cn)(0-4hr)
- The maximum plasma concentration (Cmax)(0-4hr)
研究者
相似试验
已完成
1 期
A Study to Compare Two Paracetamol Formulations.PainNCT01592227GlaxoSmithKline30
Unknown
不适用
Population Pharmacokinetics and Dosage Individualization of Paracetamol and Ibuprofen in Children With PDAPatent Ductus ArteriosusNCT04397913Shandong University500
已完成
1 期
Pharmacokinetic Interaction Between Ibuprofen and Acetaminophen, Tablets Administered Individually or in CombinationHealthyNCT05428306Laboratorios Silanes S.A. de C.V.42
已完成
1 期
Bioequivalence Study of Ibuprofen 200 mg Gel Capsules of Dr. Reddy's Laboratories Under Fasting ConditionHealthyNCT01149941Dr. Reddy's Laboratories Limited30
已完成
1 期
Bioequivalence Study of Ibuprofen 200 mg Soft Gel Capsules of Dr. Reddy's Laboratories Limited Under Fed ConditionsHealthyNCT01149954Dr. Reddy's Laboratories Limited30